Biopharma Dealmaking Quarterly Statistics, Q4 2012

A look at financing, M&A, and alliance activity October – December 2012

At $4.2 billion, biopharma financing in Q4 2012 showed a 36% increase over Q3 with FOPOs again dominating as the most popular deal type. With 34 finalized biopharma M&As, Q4 was the most active quarter of all 2012 for acquisitions. The 108 biopharma alliances completed had a combined potential deal value of almost $2 billion; Johnson & Johnson, with seven tie-ups, was the busiest pharmaco during Q4.

Biopharma financing in the final quarter of 2012 reached $4.2 billion, a 36% increase over Q3’s $3.1 billion, again boosted by a strong showing from follow-on public offerings. The fourth quarter’s total, albeit the highest single quarter total of the year, still wasn’t enough to propel 2012’s financing aggregate of $13.6 billion above the $14.1 billion raised in 2011. (See Exhibit 1.) However, keep in mind that 2011’s figure did include Shanghai Pharmaceuticals Holding Co. Ltd.’s $2 billion IPO on the Hong Kong Exchange, [See Deal] a definite outlier, and one, that when taken out of the equation, puts 2012 ahead.

Exhibit 1

More from Deal-Making

More from In Vivo